Transporters and drug therapy: Implications for drug disposition and disease

被引:338
作者
Ho, RH
Kim, RB
机构
[1] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Pediat, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Med, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Dept Pharmacol, Nashville, TN 37232 USA
关键词
D O I
10.1016/j.clpt.2005.05.011
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The efficacy of drug therapy results from the complex interplay of multiple processes that govern drug disposition and response. Most studies to date have focused on the contribution of drug-metabolizing enzymes to the drug disposition process. However, over the past decade, it has become increasingly apparent that carrier-mediated processes, or transporters, also play critical roles in the overall disposition of numerous drugs in clinical use. In addition to their roles in xenobiotic transport, drug transporters often mediate important physiologic functions via transport of endogenous substrates such as amino acids, bile acids, and hormones that are critical for maintenance of normal homeostasis. In this review we focus on the emerging field of transporter proteins in relation to the drug disposition process, with particular emphasis on clinical implications of transporters to drug-drug interactions and subsequent development of adverse effects, inter-individual variability in drug response, and human disease.
引用
收藏
页码:260 / 277
页数:18
相关论文
共 148 条
  • [61] Kartenbeck J, 1996, HEPATOLOGY, V23, P1061
  • [62] Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome
    Keitel, V
    Kartenbeck, J
    Nies, AT
    Spring, H
    Brom, M
    Keppler, D
    [J]. HEPATOLOGY, 2000, 32 (06) : 1317 - 1328
  • [63] A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2)
    Keitel, V
    Nies, AT
    Brom, M
    Hummel-Eisenbeiss, J
    Spring, H
    Keppler, D
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 2003, 284 (01): : G165 - G174
  • [64] Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences
    Kerb, R
    Brinkmann, U
    Chatskaia, N
    Gorbunov, D
    Gorboulev, V
    Mornhinweg, E
    Keil, A
    Eichelbaum, M
    Koepsell, H
    [J]. PHARMACOGENETICS, 2002, 12 (08): : 591 - 595
  • [65] The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
    Kim, RB
    Fromm, MF
    Wandel, C
    Leake, B
    Wood, AJJ
    Roden, DM
    Wilkinson, GR
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (02) : 289 - 294
  • [66] Kim RB, 1999, PHARMACEUT RES, V16, P408
  • [67] Identification of functionally variant MDR1 alleles among European Americans and African Americans
    Kim, RB
    Leake, BF
    Choo, EF
    Dresser, GK
    Kubba, SV
    Schwarz, UI
    Taylor, A
    Xie, HG
    McKinsey, J
    Zhou, S
    Lan, LB
    Schuetz, JD
    Schuetz, EG
    Wilkinson, GR
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (02) : 189 - 199
  • [68] Drugs as P-glycoprotein substrates, inhibitors, and inducers
    Kim, RB
    [J]. DRUG METABOLISM REVIEWS, 2002, 34 (1-2) : 47 - 54
  • [69] P-GLYCOPROTEIN GENE (MDR1) CDNA FROM HUMAN ADRENAL - NORMAL P-GLYCOPROTEIN CARRIES GLY185 WITH AN ALTERED PATTERN OF MULTIDRUG RESISTANCE
    KIOKA, N
    TSUBOTA, J
    KAKEHI, Y
    KOMANO, T
    GOTTESMAN, MM
    PASTAN, I
    UEDA, K
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 162 (01) : 224 - 231
  • [70] Effect of oral probenecid coadministration on the chronic toxicity and pharmacokinetics of intravenous Cidofovir in cynomolgus monkeys
    Lacy, SA
    Hitchcock, MJM
    Lee, WA
    Tellier, P
    Cundy, KC
    [J]. TOXICOLOGICAL SCIENCES, 1998, 44 (02) : 97 - 106